Literature DB >> 15118510

Age-related macular degeneration and quality of life: how to interpret a research paper in health-related quality of life.

Sanjay Sharma1, Alejandro Oliver-Fernandez.   

Abstract

PURPOSE OF REVIEW: To review how to critically appraise a research article pertaining to changes in health-related quality of life (HRQoL) related to interventions for age-related macular degeneration (AMD). RECENT
FINDINGS: We searched PubMed using a strategy that combined the text-words, "macular degeneration" and "quality of life" (n = 73; January 17, 2004), while limiting the search to "clinical trials" (n = 6; of which 3 were published within the past year). A randomized clinical trial evaluating the efficacy of self-management as an intervention for AMD has been selected to introduce the reader to the concept of how to critically review a research paper pertaining to HRQoL in AMD. Other pertinent articles used in this review include recent results published from the Age-Related Eye Disease Study and the Submacular Surgery Trial.
SUMMARY: The NEI-VFQ is a reliable, valid, and responsive tool when applied to patients with AMD. Self-management of patients with AMD has been demonstrated to improve their HRQoL by way of an internally valid randomized clinical trial. In this issue of Current Opinion in Ophthalmology, we confront the issue of how to assess the validity and importance of a research paper pertaining to the issue of quality of life. To introduce this topic, we will present a real world clinical example to better understand how quality of life may aid in medical decision making.

Entities:  

Mesh:

Year:  2004        PMID: 15118510     DOI: 10.1097/01.icu.0000124082.88389.cf

Source DB:  PubMed          Journal:  Curr Opin Ophthalmol        ISSN: 1040-8738            Impact factor:   3.761


  2 in total

Review 1.  Current treatment limitations in age-related macular degeneration and future approaches based on cell therapy and tissue engineering.

Authors:  P Fernández-Robredo; A Sancho; S Johnen; S Recalde; N Gama; G Thumann; J Groll; A García-Layana
Journal:  J Ophthalmol       Date:  2014-01-14       Impact factor: 1.909

2.  Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study.

Authors:  Jean-Marie Rakic; Anita Leys; Heidi Brié; Kris Denhaerynck; Christy Pacheco; Stefaan Vancayzeele; Christine Hermans; Karen Macdonald; Ivo Abraham
Journal:  Clin Ophthalmol       Date:  2013-09-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.